Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

ORIC Pharmaceuticals Inc. (ORIC:NASDAQ), a clinical stage oncology company focused on developing therapeutic resistance treatments, announced new stock options, according to a June 5, 2026, Stockwatch article. The company granted 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began working for ORIC in May 2026.

The company said in the release: "These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36^th) of the remaining shares vesting each one-month period thereafter. One-third (1/3^rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan."

These inducement grants were approved by ORIC's Compensation Committee of the Board of Directors.

ORIC Pharmaceuticals Inc. is an American biopharma company focused on oncology treatments and improving patients' quality of life via overcoming treatment resistance. The company's pipeline includes:

• Rinzimetostat: an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer
• Enozertinib: a brain penetrant inhibitor targeting EGFR exon 20 and EGFR atypical mutations, being developed for NSCLC

Cancer Research Needs Grow

In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to surpass four trillion doses daily by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor.  He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

The global cancer treatment sector, unfortunately, shows no signs of shrinking. A March 26, 2026, article by Kinjel Shah for Yahoo Finance claimed that cancer incidences were rising. He quoted the American Cancer Society as expecting 2.1 million new cancer cases and over 626,000 cancer-related deaths in 2026. However, technology is ever-evolving to keep up with the disease.

Shah wrote, "Emerging technologies such as genomic sequencing, artificial intelligence, and machine learning are accelerating biomarker discovery, enhancing patient stratification, and enabling earlier and more accurate diagnoses. While a universal cure remains out of reach, consistent improvements in survival rates and patient outcomes across multiple cancer types highlight the tangible benefits of these advances, particularly when combined with earlier detection and intervention."

This innovation comes at a price. In February 2026, Keith Speights wrote an article for The Motley Fool discussing rising care costs, stating that cancer treatments in the U.S. cost roughly US$200 billion in 2020 but are expected to increase to more than US$245 billion by 2030.

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Analysts Look Forward to Next Results

On June 3, 2026, David Nierengarten of Wedbush gave ORIC an "Outperform" rating after seeing the positive primary results from the Phase 3 "WU -KONG28 study of sunvozertinib monotherapy vs. platinum -based chemotherapy in 1L advanced NSCLC with EGFR exon20ins."

Later, on June 8, 2026, Robert Burns of H.C. Wainwright & Co. reiterated its "Buy" rating for the company and its price target of US$25. Burns noted a "catalyst-rich" year ahead for ORIC, such as: "(1) a program update for ORIC-944 in 2H26; (2) presentation of updated data for enozertinib monotherapy in 1L EGFR exon 20 insertion-positive NSCLC and initial results for the combination with subcutaneous amivantamab in 2H26." These catalysts are precisely why Burns will be watching the company over the next few months.

Two Drugs in the Pipeline

In its investor presentation, ORIC claims its drugs are in a late-stage clinical pipeline, noting that ". . . rinzimetostat (ORIC-944) and enozertinib (ORIC-114) [are] rapidly advancing towards potential Phase 3 initiations."

Near-term catalysts for Rinzimetostat for MCRPC are to initiate the first global Phase 3 trial in post-abiraterone mCRPC in the first half of 2026 and to provide a program update in the second half of the year.

Near-term catalysts for enozertinib for NSCLC include "1L EGFR exon 20 monotherapy data and combination data with SC amivantamab" and "1L EGFR atypical monotherapy data", in the second half of 2026.

Ownership & Share Information¹

ORIC Pharmaceuticals Inc. has a market cap of US$776.38 million, with 103.52 million shares outstanding. The company's 52-week range is US$7.23-US$14.93.

Institutions own 68.30% of shares, while Strategic Investors own 31.70%.